Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 8.58 Bn in 2025 and is expected to reach US$ 12.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
US$ 8.58 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
5.90%
2032 Value Projection:
US$ 12.81 Bn
Figure. Pulmonary Arterial Hypertension Drug Market Share (%), By Region 2025
The global pulmonary arterial hypertension drug market has been witnessing steady growth over the past few years. Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the arteries connecting the heart and lungs. The excessive pressure makes the heart work harder to pump blood through the lungs to obtain oxygen. If not treated on time, the condition can lead to worsening symptoms and even heart failure. Factors such as the growing prevalence of pulmonary arterial hypertension due to increasing risk factors, approval of new and effective treatment drugs, and improved diagnosis are driving the demand for specific drugs globally. However, high treatment costs and side effects associated with long term use of drugs continue to remain major challenges.
Market Dynamics:
The global pulmonary arterial hypertension drug market is driven by factors such as the increasing prevalence of pulmonary arterial hypertension due to growing risk factors like older age, genetic predisposition, and other medical conditions. In November 2024, according to National Library of Medicine estimates, more than 100,000 people in North America and Europe suffer from pulmonary arterial hypertension. Furthermore, approval of new drugs such as prostacyclin analogs, Endothelin receptor antagonists, Phosphodiesterase-5 inhibitors, and others which offer improved efficacy and convenience is also fueling market growth. However, the high cost of branded drugs remains a key restraint. Treatment of pulmonary arterial hypertension requires life-long medication which costs thousands of dollars every year. This limits accessibility to medication. Nevertheless, emergence of low-cost generic drugs is expected to create new opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include United Therapeutics Corporation, Actelion Pharmaceuticals (a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., and Lupin Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market
Market Segmentation
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
Soluble Guanylate Cyclase (sGC) Stimulators
Other Drug Classes
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
Oral
Intravenous
Subcutaneous
Inhalation
Type Insights (Revenue, USD Bn, 2020 - 2032)
Branded Drugs
Generic Drugs
Gender Insights (Revenue, USD Bn, 2020 - 2032)
Male
Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
United Therapeutics Corporation
Actelion Pharmaceuticals
Bayer AG
Gilead Sciences, Inc.
Merck & Co., Inc.
GlaxoSmithKline plc
Pfizer Inc.
Novartis International AG
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
Bristol-Myers Squibb Company
Arena Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Sandoz Inc.
Lupin Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Pulmonary Arterial Hypertension Drug Market, By Drug Class
Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration
Global Pulmonary Arterial Hypertension Drug Market, By Type
Global Pulmonary Arterial Hypertension Drug Market, By Gender
Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel
Global Pulmonary Arterial Hypertension Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Prostacyclin and Prostacyclin Analogs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Endothelin Receptor Antagonists (ERAs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Soluble Guanylate Cyclase (sGC) Stimulators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Drug Classes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Inhalation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Pulmonary Arterial Hypertension Drug Market, By Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Branded Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Pulmonary Arterial Hypertension Drug Market, By Gender, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Male
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Pulmonary Arterial Hypertension Drug Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)